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Abstract
Background: There is some evidence that annual vaccination of trivalent inactivated influenza vaccine (TIV) may lead to
reduced vaccine immunogenicity but evidence is lacking on whether vaccine efficacy is affected by prior vaccination history.
The efficacy of one dose of TIV in children 6–8 y of age against influenza B is uncertain. We examined whether
immunogenicity and efficacy of influenza vaccination in school-age children varied by age and past vaccination history.
Methods and Findings: We conducted a randomized controlled trial of 2009–10 TIV. Influenza vaccination history in the
two preceding years was recorded. Immunogenicity was assessed by comparison of HI titers before and one month after
receipt of TIV/placebo. Subjects were followed up for 11 months with symptom diaries, and respiratory specimens were
collected during acute respiratory illnesses to permit confirmation of influenza virus infections. We found that previous
vaccination was associated with reduced antibody responses to TIV against seasonal A(H1N1) and A(H3N2) particularly in
children 9–17 y of age, but increased antibody responses to the same lineage of influenza B virus in children 6–8 y of age.
Serological responses to the influenza A vaccine viruses were high regardless of vaccination history. One dose of TIV
appeared to be efficacious against confirmed influenza B in children 6–8 y of age regardless of vaccination history.
Conclusions: Prior vaccination was associated with lower antibody titer rises following vaccination against seasonal
influenza A vaccine viruses, but higher responses to influenza B among individuals primed with viruses from the same
lineage in preceding years. In a year in which influenza B virus predominated, no impact of prior vaccination history was
observed on vaccine efficacy against influenza B. The strains that circulated in the year of study did not allow us to study the
effect of prior vaccination on vaccine efficacy against influenza A.
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Introduction
Receipt of trivalent inactivated influenza vaccination (TIV)
should stimulate a robust immune response including rises in
humoral antibody titers against vaccine strains [1]. Rises in
antibody titer occur 2–3 weeks after vaccination and persist for
a few months [2]. The proportion of vaccine recipients achieving
post-vaccination antibody titers $1:40 by hemagglutination
inhibition (HI) is of particular interest because this threshold has
been correlated with 50% protection against infection in historical
studies [3,4], although those studies mostly did not involve
children [4]. Vaccine efficacy is measured in randomized
controlled trials as the degree of protection conferred against
laboratory-confirmed influenza virus infection.
In some countries children are recommended to receive
influenza vaccination every year, and a concern has been raised
over whether repeated vaccination affects vaccine efficacy and
long term immunity in children [5]. Previous studies examining
antibody responses to repeated influenza vaccination have been
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inconclusive [6–19]. Few studies have investigated whether
vaccine efficacy or effectiveness against laboratory-confirmed
influenza virus infection in vaccinated individuals is affected by
their vaccination history [20–23]. The current dosage recommen-
dation for children 6 months to 8 years of age also considers
vaccination history of these children [24]. Very few studies have
however evaluated the effect of previous vaccination on vaccine
efficacy or effectiveness, particularly in children between 6 years
and 8 years of age [25,26].
In a large trial we randomly allocated 796 school age children to
receive seasonal TIV or placebo [27,28]. In a separate study of 64
children who were also randomly allocated to receive TIV or
placebo in the preceding year, we reported that receipt of TIV in
the first year was associated with reduced antibody responses to
TIV in the second year for the influenza A vaccine strains which
were the same in both years [29]. As the majority of those 64
children were older than 8 years of age, we could not explore
whether prior vaccination of the same vaccine virus also affected
antibody responses in younger children. In this report, we analysed
data from all 796 children included in the trial to explore whether
the effect of prior vaccination on antibody response to TIV was
age dependent and to what extent it might affect vaccine efficacy.
We also examined the effect of previous vaccination on the efficacy
of one dose of TIV in children aged 6 to 8 years of age and 9–17
years of age against influenza B which predominated during the
study period.
Methods
Subjects and Follow Up
TIV and placebo were randomly allocated to study subjects
from August 2009 through January 2010 [28]. Eligible subjects
were between 6 and 17 years of age and not contraindicated for
receipt of TIV. At the time of enrollment, the study subjects and
their parents were interviewed by a trained research assistant to
obtain information regarding their influenza vaccination status for
the 2007–08 and 2008–09 influenza seasons (i.e. one and two
years earlier), medical history and other personal and household
demographics. Sixty-four of the children had also participated in
the study in the preceding year [27], and information on receipt of
TIV as part of that trial is included in this study.
Serum specimens were collected immediately before and 1
month after vaccination, during follow-up (April-May, 2010,
‘‘mid-study’’) and at the end of the follow up period (August-
December, 2010). All subjects and their household members were
monitored for signs and symptoms of acute upper respiratory tract
infections (URTIs) through biweekly telephone interviews and
daily symptom diaries, and reminders to notify our study team
about any illnesses. Following identification of an acute URTI in
any study subject or household member, we arranged home visits
to collect nose and throat swabs from all household members
(regardless of illness). The case definition used to trigger a home
visit was at least 2 of fever $37.8uC, cough, sore throat, headache,
chills, coryza or myalgia. The study was approved by the
Institutional Review Board of the University of Hong Kong. All
participants 18 years or older gave written informed consent.
Proxy written consent from parents or legal guardians was
obtained for persons 17 years or younger, with additional written
assent from those 8 to 17 years of age.
Vaccines
Study subjects were randomized to receive one dose of TIV
(0.5 ml VAXIGRIP, Sanofi Pasteur) or placebo (0.5 ml saline) in
the ratio 3:2. The seasonal TIV used in this study contained A/
Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like
and B/Brisbane/60/2008-like strains. The TIV and placebo were
packaged in identical syringes by trained staff not involved in
vaccine administration to preserve the double-blind study design.
Children 6–8 years old who had never received influenza
vaccination before were only given one dose of TIV, rather than
the recommended 2 doses, based on the hypothesis that children
in Hong Kong could be more experienced with influenza virus
infection so that one dose may be sufficiently immunogenic [30].
The vaccine compositions recommended by the World Health
Organization for the Northern Hemisphere in the previous years,
and used in Hong Kong, were A/Solomon Islands/3/2006
(H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like and B/Malay-
sia/2506/2004-like viruses (2007–08); and A/Brisbane/59/2007
(H1N1)-like, A/Brisbane/10/2007 (H3N2)-like and B/Florida/4/
2006-like viruses (2008–09) (Table 1). Only inactivated influenza
vaccines were licensed in Hong Kong at the time; live attenuated
influenza vaccines were first registered in Hong Kong during our
study period, and no subjects in our study reported receipt of live
attenuated influenza vaccines. Monovalent inactivated pandemic
influenza A(H1N1pdm09) vaccine became available during our
study period but community uptake was low and none of the
subjects in our study reported receipt of that vaccine.
Laboratory Methods
Serum specimens were tested by HI assays with serial dilutions
from 1:10 to 1:1280, to estimate antibody titers against the vaccine
strains A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007-like
virus A/Uruguay/716/2009 (H3N2) and B/Brisbane/60/2008
(Victoria-lineage), and the prevalent pandemic influenza strain A/
California/7/2009 (H1N1pdm09). Sera with antibody titers
$1:1280 were re-titrated to endpoint. Nose and throat swabs
were tested by reverse transcription polymerase chain reaction
(RT-PCR) for influenza A and B viruses. The HI assay and RT-
PCR were performed using standard methods as reported
previously [27,31].
Statistical Methods
Geometric mean antibody titers before and 1 month after
receipt of TIV or placebo were compared between children who
received influenza vaccination in any of the previous 2 years and
those who did not, using Wald tests after log transformation of the
antibody titers. The geometric mean titer ratio was compared
using Wald tests after log transformation of the titer ratio one
month after receipt of TIV to before receipt. Non-parametric
comparisons using Wilcoxon signed- rank tests were also
performed, using data without multiple imputations. The results
were stratified to examine whether prior vaccination had
differential effect on antibody response in younger (6–8 years
old) and older children (9–17 years old). The proportion of
children attaining antibody titer of $1:40 and $1:160 following
vaccination were compared using combined chi-squared tests.
Antibody titers ,1:10 were imputed as 1:5. Multiple imputations
for a small amount of missing data were performed using 10
imputations, to make use of all available data [32]. Multiple
imputations were performed using an algorithm involving pre-
dictive mean matching [33–35].
We used multivariable Poisson regression models allowing for
the duration of follow-up in each subject to model how the risk of
RT-PCR-confirmed influenza virus infections was affected by age,
presence of chronic health conditions, receipt of TIV/placebo and
prior vaccination history. Analyses were stratified by age, and an
interaction term between TIV/placebo and prior vaccination was
included in the models. Vaccine efficacy was estimated as (1-
Influenza Vaccination Immunogenicity and Efficacy
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e59077
incidence rate ratio)x100%. All analyses were performed using R
version 2.10.1 (R Foundation for Statistical Computing, Vienna,
Austria).
Results
Of 796 study subjects, 479 were randomized to TIV and 317 to
placebo. One subject allocated to placebo withdrew from the study
after randomization but before the intervention was administered.
Of the 479 children who received TIV, 150 (31%) of them had
received TIV in either 2007–08 or 2008–09, and 51 (11%)
children suffered from chronic health conditions such as allergic
rhinitis or asthma (Table 2). Children allocated to placebo had
similar characteristics (data not shown) [31]. The timeline and the
weekly number of influenza virus infections confirmed by RT-
PCR during the study are shown in Figure S1. Children were
followed up for a median of 351 days (interquartile range 327–371
days) following receipt of TIV/placebo, including periods when
influenza B viruses from the Victoria lineage predominated. The
activities of circulating influenza strains detected by RT-PCR in
our study closely matched with influenza circulation in Hong
Kong based on data from the reference laboratory for Hong Kong
Island at Queen Mary Hospital [31].
To explore the potential influence of age and prior vaccination
history on antibody response to vaccine, antibody titers before and
one month after receipt of 2009–10 TIV were studied among
younger (6–8 y) and older (9–17 y) school age children with
different vaccination history. The vaccine virus strains included
during the previous seasons (Northern Hemisphere) are shown in
Table 1. Individual antibody titers are shown in Figure 1 and the
corresponding summary statistics are shown in Table S1 and
Table S2. A general pattern was observed particularly among
older children on the effect of previous vaccination on antibody
response to seasonal influenza A(H1N1) and A(H3N2) vaccine
viruses. Previously vaccinated children tended to show higher pre-
vaccination antibody titer but lower post-vaccination antibody
titer to the seasonal A vaccine strains. Nevertheless, they still had
high post-vaccination antibody titers.
A different effect of previous vaccination was observed on the
antibody response to seasonal influenza B vaccine virus particu-
larly among younger children. There were a considerable number
of younger children who failed to mount a high antibody response
to the 2009–10 study TIV if they had not had previously received
the 2007–08 vaccine which included a Victoria-lineage influenza
B virus. Receipt of the 2007–08 vaccine was associated with an
improved antibody response to 2009–10 vaccine virus of the same
lineage. However, similar enhancement effect was not observed if
the previous influenza B vaccine virus belonged to the Yamagata-
lineage.
The pandemic influenza A(H1N1) virus was not included in any
of the 2007–08, 2008–09 or 2009–10 vaccines. Neither the 2007–
08 or 2008–09 TIV appeared to affect antibody response to the
2009–10 TIV against pandemic influenza A(H1N1). However, it
appears that older children who had received TIV for 3
consecutive years showed small increase in antibody titer to
pandemic influenza A(H1N1) virus. It is uncertain whether that
might have been affected by recent infections with the circulating
pandemic influenza A(H1N1) virus.
For comparison we investigated the subjects who received
placebo in 2009–10 and we found that previous vaccination did
not affect antibody response to placebo and the antibody profile
was consistent with vaccination history (Figure S2, Table S3 and
Table S4).
Table 1. Antigenic relationship between vaccine virus strains included in the trivalent inactivated influenza vaccines for the 2007–
2010 seasons (Northern Hemisphere).
Season Seasonal influenza A(H1N1) Seasonal influenza A(H3N2) Seasonal influenza B
2007–2008 [41] A/Solomon Islands/3/2006 A/Wisconsin/67/2005 B/Malaysia/2506/2004 (Victoria-lineage)
2008–2009 [42] A/Brisbane/59/2007 (Cross reactive
with post A/Solomon
Islands/3/2006 infection ferret
sera [43])
A/Brisbane/10/2007 (Highly cross
reactive with post
A/Wisconsin/67/2005
infection ferret sera [43])
B/Florida/4/2006 (Yamagata-lineage)
2009–2010 [44] Same as previous year Same as previous year B/Brisbane/60/2008 (Victoria-lineage)
doi:10.1371/journal.pone.0059077.t001
Table 2. Characteristics of 479 subjects randomized to receive trivalent inactivated influenza vaccine (TIV) in 2009–10 with regard
to their vaccination history in 2007–08 and 2008–09.
Not received TIV
in 2007–08
or 2008–09
Received TIV in
2007–08 only
Received TIV in
2008–09 only
Received TIV in
2007–08
& 2008–09
Incomplete
vaccination
history
n (%) n (%) n (%) n (%) n (%)
6–8 years of age 94 15 40 17 4 (2)
Male 44 (47) 12 (80) 20 (50) 8 (47)
Presence of chronic health conditions 7 (7) 1 (7) 4 (10) 1 (6)
9–17 years of age 221 22 41 15 10 (3)
Male 110 (50) 14 (64) 22 (54) 11 (73)
Presence of chronic health conditions 28 (13) 5 (23) 3 (7) 2 (13)
doi:10.1371/journal.pone.0059077.t002
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To investigate whether previous vaccination affected vaccine
efficacy, the incidence of RT-PCR confirmed influenza infection
among the children was examined. Influenza B virus (Victoria-
lineage) dominated during the study and detection rate of
Figure 1. Individual antibody titers before and one month after receipt of trivalent inactivated influenza vaccine (TIV) in 2009–2010
among 6–8 y (Y, represented by blue circles) and 9–17 y children (O, represented by grey circles) with regard to their vaccination
history for the 2007–2008 and 2008–2009 seasons. The median and interquartile range of antibody titers are shown, p-values were obtained
by non parametric Wilcoxon signed rank tests. The comparisons were made with reference to children who were randomized to receive TIV in 2009–
10 but did not receive any TIV during 2007–2008 and 2008–2009 seasons. The two p-values shown in each plot were obtained by comparison with
children of the same age in the corresponding reference group (6–8 y and 9–17 y).
doi:10.1371/journal.pone.0059077.g001
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influenza A viruses was low (Figure S1). Table 3 shows TIV had
60–70% efficacy against confirmed influenza B virus infection in
all age groups regardless of vaccination history. There was no
evidence that previous vaccination negatively affected vaccine
efficacy. The results also show 1 dose of TIV was of comparable
efficacy in preventing seasonal influenza B among 6–8 y Hong
Kong children even if they had not been vaccinated in recent
years. Further study is however required to confirm the efficacy
against influenza A.
Discussion
While past vaccination history did affect the antibody responses
to TIV, we found that vaccine efficacy against confirmed influenza
B did not appear to be affected by past vaccination history. Our
estimates for vaccine efficacy were consistent with the values
typically observed in other studies in the range 60%–70% [36].
There is little information in the literature on how previous
influenza vaccination might affect vaccine efficacy. A number of
studies have demonstrated that repeated annual vaccination can
lead to poorer antibody responses [6–14,20], although this is not
always the case [8,18,19].
In our previous study, we reported reduced antibody response
to seasonal influenza A(H1N1) and A(H3N2) vaccine virus in
children aged 6–17 years if the vaccine viruses remained
unchanged from the previous year [29]. In this report, we
explored the role of antigenic similarity and age on the interaction
of previous vaccination on antibody response to TIV. We found
that previous exposure of the same seasonal influenza A(H1N1)
and A(H3N2) vaccine virus reduced antibody response to TIV,
and the effect appeared to be more profound in older children.
The effect of previous exposure to antigenically related seasonal
influenza A(H1N1) and A(H3N2) vaccine viruses included in the
2007–08 influenza vaccine was also found to negatively affect
antibody response. However, it remains unclear whether this
change in immunogenicity translates into any changes in
vaccination efficacy due to low circulation of seasonal influenza
A(H1N1) and A(H3N2) viruses during the study. Furthermore,
most of the vaccinated children attained post-vaccination antibody
titers of $1:40 to seasonal influenza A(H1N1) and A(H3N2)
viruses regardless of vaccination history.
It was observed in this study that 1 dose of TIV elicited lower
antibody responses to influenza B among children aged 6–8 y if
they had not been recently vaccinated although this did not appear
to lead to lower efficacy. Previous vaccination was only observed to
improve antibody response to influenza B vaccine virus if the
current vaccine strain belonged to the same virus lineage. It is
uncertain if the dosage recommendation for 6 m-9 y children
should also consider the lineage of influenza B vaccine virus they
had previously received. However this may not be feasible in
practice, and a preferable solution could be the introduction of
quadrivalent influenza vaccines covering both Victoria and
Yamagata lineages. It remains to be determined whether antibody
response measured by the HI assay is a good predictor of
protection and whether current threshold for vaccine licensure is
appropriate in children. There remain uncertainties about the
50% protective antibody titer in children [37,38]. In our study we
observed that TIV remained efficacious even though some
children showed low antibody titers after vaccination.
Table 3. Factors affecting risk of RT-PCR confirmed influenza B infection and vaccine efficacy (VE) of trivalent inactivated influenza
vaccine (TIV) in 2009–10.
n RR (95% CI) P-value VE (95% CI)
6–8 years of age
Model 1 Placebo 104 1.00
TIV, not vaccinated in 2007–08 136 0.23 (0.06, 0.83) 0.02 77% (17%, 84%)
TIV, vaccinated in 2007–08 32 0.30 (0.04, 2.39) 0.26 70% (2139%, 96%)
Model 2 Placebo 104 1.00
TIV, not vaccinated in 2008–09 109 0.38 (0.12, 1.21) 0.10 62% (221%, 88%)
TIV, vaccinated in 2008–09 57 – –
Model 3 Placebo 104 1.00
TIV, not vaccinated in 2007–08 or 2008–09 98 0.33 (0.09, 1.20) 0.09 67% (220%, 67%)
TIV, vaccinated in 2007–08 or 2008–09 72 0.14 (0.02, 1.06) 0.06 86% (26%, 98%)
9–17 years of age
Model 1 Placebo 213 1.00
TIV, not vaccinated in 2007–08 262 0.33 (0.12, 0.93) 0.04 67% (7%, 88%)
TIV, vaccinated in 2007–08 37 0.45 (0.06, 3.52) 0.45 55% (2252%, 94%)
Model 2 Placebo 213 1.00
TIV, not vaccinated in 2008–09 245 0.36 (0.13, 1.02) 0.05 64% (22%, 87%)
TIV, vaccinated in 2008–09 61 0.29 (0.04, 2.20) 0.23 71% (2120%, 96%)
Model 3 Placebo 213 1.00
TIV, not vaccinated in 2007–08 or 2008–09 226 0.32 (0.10, 0.98) 0.05 68% (2%, 68%)
TIV, vaccinated in 2007–08 or 2008–09 83 0.42 (0.25, 1.89) 0.26 58% (289%, 75%)
Footnote: Relative risks (RR) were approximated by the incidence rate ratio, adjusted for presence of chronic health conditions. ‘‘–’’ represents statistic that could not be
estimated due to lack of RT-PCR confirmed influenza B infection in this category.
doi:10.1371/journal.pone.0059077.t003
Influenza Vaccination Immunogenicity and Efficacy
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e59077
There are several limitations in our study. Firstly, previous
receipt of influenza vaccine was within the discretion of the
participants and their parents. Any systematic differences among
previously vaccinated children might have confounded our results.
It was reassuring that the antibody profile of children receiving
placebo did not differ by vaccination history. The patterns in
antibody response was also consistent with our previous study on
the subset of 64 children who had also been randomly allocated to
TIV/placebo in the preceding year [29]. However, ascertainment
bias might still occur if previously vaccinated children were more
likely to report their illness. On the other hand, it is also possible
that these parents may adopt better household and personal
hygiene measures so that previously vaccinated children may be
less exposed to influenza viruses. As parents might have difficulty
recalling earlier vaccination history, only vaccination history of
2007–08 and 2008–09 was obtained. Errors in self-reported
vaccination history and smaller numbers of younger children may
have also affected our power to detect differences in risk of
confirmed infections. However, the antibody profile generally
matched with the reported vaccination history in our study. One
other limitation is that only a small proportion of children reported
previous vaccination and this limited the power of our study to
detect changes in vaccine efficacy in relation to vaccination
history. It has been reported that HI may not detect protective
antibody that do not bind to the haemagglutinin [39] and HI titer
may not be strongly correlated with immunity to influenza. We did
not measure neutralizing antibodies in our study, although there is
limited information in the literature on how neutralizing
antibodies may provide additional information on protection
against infection compared with HI titers [40]. While our study
did not find that previous vaccination affected vaccine efficacy
against influenza B, further study is required to confirm whether
repeated exposure of antigenically identical or related influenza A
vaccine viruses may affect vaccine efficacy. It is also noted that the
peri-pandemic period may not be the best time to study
immunogenicity and efficacy of seasonal influenza vaccine
although influenza B did predominate in our study period.
In conclusion, antibody responses in children to the strains
included in the 2009–10 seasonal TIV were affected by age and
previous vaccination history. Previously vaccinated children
showed reduced antibody responses against seasonal A(H1N1)
and seasonal A(H3N2) particularly in older children. Regardless of
past influenza vaccination history, antibody titers to seasonal
influenza A were raised to high levels following administration of
TIV in children in our study. Previous vaccination was associated
with higher antibody responses to influenza B in younger children
although we did not find any effect on vaccine efficacy. The strains
that circulated in the year of study did not allow us to study the
effect of prior vaccination on vaccine efficacy against influenza A.
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